Y
Yantai Lannacheng Biotechnology
A company working with drug synthesis, radioactive labeling, preclinical cell and animal experiments, and molecular imaging
About Yantai Lannacheng Biotechnology
Yantai Lannacheng Biotechnology Co., Ltd. (LNC) is a clinical-stage biopharmaceutical company established in 2021 as a joint venture between Yantai Dongcheng Pharmaceutical Group, a prominent Chinese nuclear medicine enterprise, and Professor Xiaoyuan (Shawn) Chen, an expert in molecular imaging and nanomedicine. The company focuses on the development and registration of first-in-class, integrated radiotheranostics for oncological applications.
LNC's business strategy centers on creating its own pipeline of proprietary drug assets and then out-licensing them to larger biopharmaceutical partners who manage late-stage trials and commercialization. The company has successfully raised significant capital to fund its research and development, including a Series B+ financing round of 300 million RMB in April 2024, led by Shenzhen Capital Group. This followed earlier Series A and B funding rounds in 2022 and 2023, respectively.
The company's core technology revolves around a proprietary "albumin binder-Evans blue modification" platform, which enhances the tumor retention and absorbed dose of radiopharmaceuticals, allowing for potentially reduced dosages and less frequent administration. LNC's product pipeline is built upon this platform and includes radioligands based on small molecules, peptides, and antibodies. These products target a variety of solid tumors, such as prostate cancer, gastric cancer, gliomas, and neuroendocrine tumors, by targeting proteins like Fibroblast Activation Protein (FAP) and Prostate-Specific Membrane Antigen (PSMA). Several of its candidates have received Investigational New Drug (IND) approvals from regulatory bodies in the US, Singapore, and China and are advancing through clinical trials.
To support its R&D, LNC invested over 100 million RMB to build a 6,500-square-meter comprehensive laboratory in Yantai's "MediPark," which became operational in 2023. This facility integrates drug synthesis, radiolabeling, preclinical studies, and molecular imaging, forming the company's core translational medicine platform. Headquartered in Yantai, the company also operates a subsidiary in Singapore, LNC Pharma Pte. Ltd., to manage international affairs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 54.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jul 2025 | $41M | $550M | China Cinda Asset Management · Yantai Dongcheng Pharmaceutical · Shandong New Growth Drivers Fund | ↗ |
| SERIES BOther financing | Apr 2024 | $41M | $309M | Aowa Clean Energy · Shenzhen Capital Group · Qianhai FOF · Yantai Finance Development Investment Group | ↗ |
Growth signals
Latest recorded traffic for Yantai Lannacheng Biotechnology is 400 monthly website visits, up 900% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yantai Lannacheng Biotechnology in its local ecosystem
The Yantai Lannacheng Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- AEAowa Clean Energy
Shenzhen Capital Group
Qianhai FOF- YGYantai Finance Development Investment Group
- LILongxin Investment
Series B and later3 investors entered at this stage
China Cinda Asset Management
Yantai Dongcheng Pharmaceutical
Shandong New Growth Drivers Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yantai Lannacheng Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yantai Lannacheng Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








